EDMONTON, Alberta (September 1, 2020) – The Canadian Glycomics Network (GlycoNet) is pleased to announce the promotion of Dr. Elizabeth Nanak from Executive Director to Chief Executive Officer, effective immediately.

Dr. Nanak has been with GlycoNet since its conception in 2015 and served as the Executive Director since the launch of the Network. During her tenure, she was responsible for the development of strategic and operation plans, oversaw the implementation of several programs critical to GlycoNet’s portfolio, and more recently, co-led the successful renewal of GlycoNet, which provided the Network a $16.3-million commitment from the Networks of Centres of Excellence for the next three years. Along with GlycoNet’s leadership team, Dr. Nanak will take GlycoNet to the next phase of improving the health of Canadians through scientific knowledge and technologies built upon glycoscience. Dr. Nanak earned her PhD in biochemistry from the Université de Technologie de Compiègne, and her MBA in biotechnology management from the University of Saskatchewan.

“GlycoNet is fortunate to have an excellent executive team leading the Network during these challenging times,” said Ms. Karimah Es Sabar, Chair of Board of Directors at GlycoNet. “It is imperative that as the leading organization in glycomics, we push ahead post-COVID-19 to continue to make positive impacts on Canadian healthcare. With Elizabeth as CEO, I am confident that GlycoNet will continue to fulfill that mission.”

About GlycoNet
GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians. GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. Funded by the federal Networks of Centres of Excellence (NCE) program and a range of partners, the network includes over 150 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training.

More information
Ali Chou
Communications Associate
ychou@glyconet.ca
780-231-5181